Anterogen.Co.,Ltd. (KOSDAQ:065660)
South Korea flag South Korea · Delayed Price · Currency is KRW
22,200
-1,000 (-4.31%)
May 13, 2025, 3:30 PM KST
51.02%
Market Cap 222.14B
Revenue (ttm) 6.93B
Net Income (ttm) -2.29B
Shares Out 10.01M
EPS (ttm) -236.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,870
Average Volume 27,486
Open 23,200
Previous Close 23,200
Day's Range 22,150 - 23,400
52-Week Range 13,100 - 23,650
Beta 0.44
RSI 55.62
Earnings Date n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 065660
Full Company Profile

Financial Performance

In 2024, Anterogen.Co.,Ltd.'s revenue was 6.93 billion, an increase of 6.66% compared to the previous year's 6.50 billion. Losses were -2.29 billion, -19.29% less than in 2023.

Financial Statements

News

There is no news available yet.